0.7987  0.099 (14.07%)		02-19 16:00
Open: 0.7214 High: 0.8999 Volume: 483,395		Pre. Close: 0.7002 Low: 0.715 Market Cap: 6(M)

Short term
Mid term
Targets	6-month :	0.97	1-year :	1.08
Resists	First :	0.83	Second :	0.93
Pivot price	0.76
Supports	First :	0.67	Second :	0.55
MAs	MA(5) :	0.72	MA(20) :	0.79
	MA(100) :	0.86	MA(250) :	0.92
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	27.4	D(3) :	16.7
RSI	RSI(14): 46.8
52-week	High :	3.78	Low :	0.28

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ KTTA ] has closed below upper band by 38.4%. Bollinger Bands are 31.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.86 - 0.86	0.86 - 0.86
Low:	0.71 - 0.71	0.71 - 0.71
Close:	0.79 - 0.8	0.8 - 0.8

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Tue, 17 Feb 2026
Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Investing News Network

Tue, 17 Feb 2026
NF1-PN drug developer Pasithea to present at Oppenheimer event - Stock Titan

Mon, 16 Feb 2026
Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Bitget

Mon, 08 Dec 2025
HC Wainwright & Co. Initiates Coverage of Pasithea Therapeutics (KTTA) with Buy Recommendation - Nasdaq

Thu, 04 Dec 2025
Pasithea Therapeutics Reaches US$104m Market Cap Benefiting Insider Stock Buying - simplywall.st

Thu, 04 Dec 2025
Insiders Buying Pasithea Therapeutics Might Wish They Invested More, Stock Gains 10% - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	23 (M)
Shares Float	6 (M)
Held by Insiders	1.6 (%)
Held by Institutions	22.3 (%)
Shares Short	367 (K)
Shares Short P.Month	452 (K)

EPS	-4.45
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.63
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-53.8 %
Return on Equity (ttm)	-90 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.58
Qtrly Earnings Growth	0 %
Operating Cash Flow	-12 (M)
Levered Free Cash Flow	-8 (M)

PE Ratio	-0.18
PEG Ratio	0
Price to Book value	0.48
Price to Sales	0
Price to Cash Flow	-1.51

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.